Oncology

News

Astellas scores first US blood cancer approval with Xospata

The FDA has approved Astellas’ Xospata for certain patients with acute myeloid leukaemia – the company’s first drug approved in blood cancer.

Views & Analysis

Merck & Co’s cancer blockbuster Keytruda funds cutting edge ...

Merck & Co is enjoying blockbuster revenues as its cancer immunotherapy Keytruda is becoming standard of care in a range of cancers.

News

Blockchain firm Witty Health launches digital cancer decisio...

The health blockchain technology firm Witty Health has launched OncoPower, a digital tool helping oncologists with their decision making.

News

AstraZeneca on course to long term growth, says CEO

AstraZeneca’s CEO Pascal Soriot has said the company has returned to long-term growth following a difficult period where patents on key products expired.

News

Chronic lymphocytic leukemia (CLL) is a type of cancer of the blood and bone marrow - the spongy tissue inside bones where blood cells are made.

AbbVie's CLL drug Venclyxto too expensive for NHS, says NICE

NICE has said AbbVie’s Venclyxto (venetoclax), in combination with development partner Roche's MabThera/Rituxan (rituximab), is not a cost-effective use of NHS resources as a treatment for

News

BMS invests $12m in cancer immunotherapy tie-up with Compuge...

Bristol-Myers Squibb has invested $12 million in Compugen, a biotech that is investigating a new approach that could boost the effectiveness of its blockbuster cancer immunotherapy Opdivo.<

Astellas scores first US blood cancer approval with Xospata

Merck & Co’s cancer blockbuster Keytruda funds cutting edge ...

Blockchain firm Witty Health launches digital cancer decisio...

AstraZeneca on course to long term growth, says CEO

AbbVie's CLL drug Venclyxto too expensive for NHS, says NICE

BMS invests $12m in cancer immunotherapy tie-up with Compuge...

FDA starts review of Regeneron's drug for rare disease FOP

How to meet your physicians where they are online

Oncology

Editor's Picks